Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Incidence, risk factors, and management of infusion-related reactions in breast cancer patients receiving trastuzumab.

Thompson LM, Eckmann K, Boster BL, Hess KR, Michaud LB, Esteva FJ, Hortobágyi GN, Barnett CM.

Oncologist. 2014 Mar;19(3):228-34. doi: 10.1634/theoncologist.2013-0286.

2.

Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.

Berger MJ, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro CL, Lustberg MB.

Support Care Cancer. 2015 Jul;23(7):2019-24. doi: 10.1007/s00520-014-2556-x.

3.

Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study.

Bowles EJ, Wellman R, Feigelson HS, Onitilo AA, Freedman AN, Delate T, Allen LA, Nekhlyudov L, Goddard KA, Davis RL, Habel LA, Yood MU, McCarty C, Magid DJ, Wagner EH; Pharmacovigilance Study Team..

J Natl Cancer Inst. 2012 Sep 5;104(17):1293-305. doi: 10.1093/jnci/djs317.

4.

[Short-term safety evaluation of trastuzumab administrated intravenously over 30 minutes with 100 mL saline solution with a focus on infusion reaction].

Hasegawa Y, Miura M, Sato K, Yamanaka Y, Narita J, Shibata S, Suto T.

Gan To Kagaku Ryoho. 2013 Dec;40(13):2545-9. Japanese.

PMID:
24335367
5.

Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab.

Parthan A, Santos E, Becker L, Small A, Lalla D, Brammer M, Teitelbaum A.

J Manag Care Spec Pharm. 2014 May;20(5):485-93.

6.

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial.

Pivot X, Romieu G, Debled M, Pierga JY, Kerbrat P, Bachelot T, Lortholary A, Espié M, Fumoleau P, Serin D, Jacquin JP, Jouannaud C, Rios M, Abadie-Lacourtoisie S, Tubiana-Mathieu N, Cany L, Catala S, Khayat D, Pauporté I, Kramar A; PHARE trial investigators..

Lancet Oncol. 2013 Jul;14(8):741-8. doi: 10.1016/S1470-2045(13)70225-0.

PMID:
23764181
7.

Trastuzumab-induced cardiotoxicity in early breast cancer patients: a retrospective study of possible risk and protective factors.

Farolfi A, Melegari E, Aquilina M, Scarpi E, Ibrahim T, Maltoni R, Sarti S, Cecconetto L, Pietri E, Ferrario C, Fedeli A, Faedi M, Nanni O, Frassineti GL, Amadori D, Rocca A.

Heart. 2013 May;99(9):634-9. doi: 10.1136/heartjnl-2012-303151.

PMID:
23349345
8.

Cetuximab hypersensitivity infusion reactions: Incidence and risk factors.

Hopps S, Medina P, Pant S, Webb R, Moorman M, Borders E.

J Oncol Pharm Pract. 2013 Sep;19(3):222-7. doi: 10.1177/1078155212462440.

PMID:
23135806
9.

Severe infusion reactions to cetuximab occur within 1 h in patients with metastatic colorectal cancer: results of a nationwide, multicenter, prospective registry study of 2126 patients in Japan.

Yamaguchi K, Watanabe T, Satoh T, Ishiguro M, Izawa M, Inoshiri S, Sugihara K, Sakata Y.

Jpn J Clin Oncol. 2014 Jun;44(6):541-6. doi: 10.1093/jjco/hyu049.

10.

Trastuzumab-related cardiac events in the treatment of early breast cancer.

Fried G, Regev T, Moskovitz M.

Breast Cancer Res Treat. 2013 Nov;142(1):1-7. doi: 10.1007/s10549-013-2732-6.

PMID:
24154507
11.

CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).

Pestalozzi BC, Holmes E, de Azambuja E, Metzger-Filho O, Hogge L, Scullion M, Láng I, Wardley A, Lichinitser M, Sanchez RI, Müller V, Dodwell D, Gelber RD, Piccart-Gebhart MJ, Cameron D.

Lancet Oncol. 2013 Mar;14(3):244-8. doi: 10.1016/S1470-2045(13)70017-2.

PMID:
23414588
12.
13.

[An unexpected and severe infusion reaction induced by trastuzumab].

Sacramento Díaz-Carrasco M, Ramírez C, Montenegro S, Alonso-Romero JL.

Farm Hosp. 2014 May 1;38(3):254-5. doi: 10.7399/fh.2014.38.3.1169. Spanish.

14.

Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).

de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-Jones B, Dowsett M, Gelber RD, Piccart-Gebhart MJ, Suter TM.

J Clin Oncol. 2014 Jul 10;32(20):2159-65. doi: 10.1200/JCO.2013.53.9288.

PMID:
24912899
15.

Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer.

Russo G, Cioffi G, Gori S, Tuccia F, Boccardi L, Khoury G, Lestuzzi C, Maurea N, Oliva S, Faggiano P, Tarantini L; ICARO (Italian CARdio-Oncological) Network..

J Cardiovasc Med (Hagerstown). 2014 Feb;15(2):141-6. doi: 10.2459/JCM.0b013e328365afb5.

PMID:
24534802
16.

Trastuzumab-induced cardiomyopathy: incidence and associated risk factors in an inner-city population.

Baron KB, Brown JR, Heiss BL, Marshall J, Tait N, Tkaczuk KH, Gottlieb SS.

J Card Fail. 2014 Aug;20(8):555-9. doi: 10.1016/j.cardfail.2014.05.012.

PMID:
24905295
17.
18.

CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.

Pivot X, Manikhas A, Żurawski B, Chmielowska E, Karaszewska B, Allerton R, Chan S, Fabi A, Bidoli P, Gori S, Ciruelos E, Dank M, Hornyak L, Margolin S, Nusch A, Parikh R, Nagi F, DeSilvio M, Santillana S, Swaby RF, Semiglazov V.

J Clin Oncol. 2015 May 10;33(14):1564-73. doi: 10.1200/JCO.2014.57.1794.

PMID:
25605838
19.

Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study.

Pivot X, Gligorov J, Müller V, Barrett-Lee P, Verma S, Knoop A, Curigliano G, Semiglazov V, López-Vivanco G, Jenkins V, Scotto N, Osborne S, Fallowfield L; PrefHer Study Group..

Lancet Oncol. 2013 Sep;14(10):962-70. doi: 10.1016/S1470-2045(13)70383-8.

PMID:
23965225
20.

Effect of adjuvant/neoadjuvant trastuzumab on clinical outcomes in patients with HER2-positive metastatic breast cancer.

Murthy RK, Varma A, Mishra P, Hess KR, Young E, Murray JL, Koenig KH, Moulder SL, Melhem-Bertrandt A, Giordano SH, Booser D, Valero V, Hortobagyi GN, Esteva FJ.

Cancer. 2014 Jul 1;120(13):1932-8. doi: 10.1002/cncr.28689.

Items per page

Supplemental Content

Support Center